Hepatic glucose production is elevated in obesity and type 2 diabetes, contributing to the hyperglycemia that occurs in these conditions. In a new study, Liangyou Rui and colleagues show that NF-κB–inducing kinase (NIK) is abnormally activated in states of obesity, resulting in elevated hepatic glucose production. When they inhibit NIK activity in the liver, hyperglycemia is lowered, suggesting NIK as a potential therapeutic target in the management of type 2 diabetes.
- Liang Sheng
- Yingjiang Zhou
- Liangyou Rui
